一分钟看懂
这是一项关于胆道癌的II 期研究，登记的药物或干预包括Ivonescimab；GEMOX Regimen，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ivonescimab；GEMOX Regimen · II 期
登记条件中文摘要
年龄范围：18岁至80岁
登记的基本范围为不限性别，年龄18岁至80岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · 北京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * 1\. Subjects voluntarily participate in the study, agree to sign a written informed consent form, demonstrate good compliance, and are willing to cooperate with follow-up.
- * 2\. Male or female aged \>= 18 and \<= 80 years at the time of signing the ICF.
- * 3\. Histologically or cytologically confirmed biliary tract cancer (BTC, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer), and radiologically assessed as locally advanced or with oligometastases (defined as Stage IIIA or higher lesions according to the 8th edition of the AJCC staging system). Subjects must agree to provide archived or fresh tumor biopsy specimens and peripheral blood samples for biomarker testing.
- * 4\. Lesion assessment meets one of the following conditions:
- * Neoadjuvant Therapy Cohort: The tumor is graded as locally advanced with no distant metastasis, and theoretically can achieve radical resection through complex resection combined with vascular reconstruction, but both the surgical risk and postoperative recurrence risk are high (single tumor diameter \> 5 cm; imaging suggests vascular invasion or hilar lymph node metastasis; tumor number \> 3 or any single tumor \> 3 cm; preoperative CA19-9 \> 37 U/mL or exceeding the upper limit of normal \[applicable to centers where the normal range is not \< 37 U/mL\]).
- * Conversion Therapy Cohort: The tumor is graded as locally advanced, unresectable, or combined with oligometastatic status (oligometastasis is defined as: metastatic lesions confined to a single organ or specific regional lymph nodes, and the number of metastatic lesions is \<= 5), with the possibility of achieving radical resection of the primary lesion and no evidence of disease (NED) status for metastatic lesions after comprehensive treatment.
- * 5\. At least one measurable lesion (according to RECIST v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan \>= 10 mm or the shortest diameter of enlarged lymph nodes \>= 15 mm).
- * 6\. No prior systemic therapy for biliary tract cancer.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07854600；登记信息更新于 2026-10-02；本站同步于 2026-10-08，中国中心当前名额未经人工确认。